The Food and Drug Administration recently granted Gilead Sciences priority review for its much-awaited hepatitis C drug sofosbuvir. Current treatments are far from perfect for the 3.2 million people suffering from chronic forms of the disease. This novel oral therapy has a lot going for it, which has some analysts thinking it could potentially hit $5 billion in peak sales. In the following video, Fool contributor Maxx Chatsko explains how Gilead's drug raises the bar for the future of hepatitis C treatment.
As mentioned in the video, AbbVie is also developing a next generation drug for hepatitis C. It has shown tremendous promise in clinical trials, but will it be enough once the company's golden goose, Humira, is cooked? The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article Gilead's Potential Megablockbuster Raises the Bar originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.